The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, showcased significant advancements in the treatment of kidney and bladder cancers. Dr. Viktor Grünwald presented a detailed follow-up analysis from the CLEAR trial, focusing on the combination therapy of lenvatinib plus pembrolizumab versus sunitinib for advanced clear cell renal cell carcinoma (ccRCC).
The primary analysis of the phase 3 CLEAR trial revealed that lenvatinib plus pembrolizumab significantly improved overall survival compared to sunitinib, a finding that was further substantiated in the final pre-specified overall survival analysis. This report delved into the patterns of progression and subsequent therapy, offering insights into the treatment's efficacy across different organs affected by the disease.
Patients treated with lenvatinib plus pembrolizumab experienced a prolonged time to tumor progression in all assessed organs, including bone, central nervous system, kidney, liver, lung, and lymph nodes. At the time of overall disease progression, the median tumor burden of target lesions was notably lower in the lenvatinib plus pembrolizumab group compared to the sunitinib group.
Furthermore, the study highlighted the duration of second-line treatments, with patients in the lenvatinib plus pembrolizumab arm remaining on axitinib or cabozantinib longer than those in the sunitinib arm. This data underscores the combination therapy's potential as a standard-of-care first-line treatment for patients with advanced ccRCC.
Presented by Dr. Viktor Grünwald, MD, PhD, from the University Hospital Essen, Germany, these findings contribute valuable knowledge to the field of genitourinary oncology, reinforcing the efficacy of lenvatinib plus pembrolizumab in managing advanced renal cell carcinoma.
